Figure 4

![Figure 4: Risk of bias assessment for the included PRP studies in immune-mediated alopecias reveals methodological variability across trials, with several domains rated as unclear or high risk due to small sample sizes and lack of blinding.]()

> Source: Kasama Tejapira et al. "Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A sys." *Frontiers in medicine*, 2022. PMID: [36507528](https://pubmed.ncbi.nlm.nih.gov/36507528/)

<figure>
  <img src="" alt="Risk of bias assessment for the included PRP studies in immune-mediated alopecias reveals methodological variability across trials, with several domains rated as unclear or high risk due to small sample sizes and lack of blinding." />
  <figcaption>Figure 4. Risk of bias assessment for the included PRP studies in immune-mediated alopecias reveals methodological variability across trials, with several domains rated as unclear or high risk due to small sample sizes and lack of blinding.<br>  Source: Kasama Tejapira et al. "Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A sys." <em>Frontiers in medicine</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36507528/">36507528</a></figcaption>
</figure>